Skip to main content
. Author manuscript; available in PMC: 2023 Jan 6.
Published in final edited form as: Cancer Discov. 2022 Jul 6;12(7):1625–1633. doi: 10.1158/2159-8290.CD-21-1683

Fig. 2: Broadening product availability.

Fig. 2:

The use of gene-edited allogeneic (‘off-the-shelf’) TCR/CAR T cells could provide immediate availability of cryopreserved cells, increase product quality, and decrease costs by using an industrial process. Beyond T cells, natural killer (NK) cells could be used as an allogeneic cellular immunotherapy.